Age, Tumor Characteristics, and Treatment Regimen as Event Predictors in Ewing: A Children's Oncology Group Report

Neyssa Marina, Linda Granowetter, Holcombe E. Grier, Richard B. Womer, R Randall, Karen J. Marcus, Elizabeth McIlvaine, Mark Krailo

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose. To associate baseline patient characteristics and relapse across consecutive COG studies. Methods. We analyzed risk factors for LESFT patients in three randomized COG trials. We evaluated age at enrollment, primary site, gender, tumor size, and treatment (as randomized). We estimated event-free survival (EFS, Kaplan-Meier) and compared risk across groups (log-rank test). Characteristics were assessed by proportional hazards regression with the characteristic of interest as the only component. Confidence intervals (CI) for RR were derived. Factors related to outcome at level 0.05 were included in a multivariate regression model. Results. Between 12/1988 and 8/2005, 1444 patients were enrolled and data current to 2001, 2004, or 2008 were used. Patients were with a median age of 12 years (0-45), 55% male and 88% Caucasian. The 5-year EFS was 68.3% ± 1.3%. In univariate analysis age, treatment, and tumor location were identified for inclusion in the multivariate model, and all remained significant (p < 0.01). Since tumor size was not collected in the last study, the other two were reanalyzed. This model identified age, treatment, tumor location, and tumor size as significant predictors. Conclusion. Age > 18 years, pelvic tumor, size > 8 cms, and chemotherapy without ifosfamide/etoposide significantly predict worse outcome. AEWS0031 is NCT00006734, INT0091 and INT0054 designed before 1993 (unregistered).

Original languageEnglish (US)
Article number927123
JournalSarcoma
Volume2015
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Neoplasms
Ifosfamide
Etoposide
Therapeutics
Disease-Free Survival
Confidence Intervals
Recurrence
Drug Therapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Marina, N., Granowetter, L., Grier, H. E., Womer, R. B., Randall, R., Marcus, K. J., ... Krailo, M. (2015). Age, Tumor Characteristics, and Treatment Regimen as Event Predictors in Ewing: A Children's Oncology Group Report. Sarcoma, 2015, [927123]. https://doi.org/10.1155/2015/927123

Age, Tumor Characteristics, and Treatment Regimen as Event Predictors in Ewing : A Children's Oncology Group Report. / Marina, Neyssa; Granowetter, Linda; Grier, Holcombe E.; Womer, Richard B.; Randall, R; Marcus, Karen J.; McIlvaine, Elizabeth; Krailo, Mark.

In: Sarcoma, Vol. 2015, 927123, 01.01.2015.

Research output: Contribution to journalArticle

Marina, N, Granowetter, L, Grier, HE, Womer, RB, Randall, R, Marcus, KJ, McIlvaine, E & Krailo, M 2015, 'Age, Tumor Characteristics, and Treatment Regimen as Event Predictors in Ewing: A Children's Oncology Group Report', Sarcoma, vol. 2015, 927123. https://doi.org/10.1155/2015/927123
Marina, Neyssa ; Granowetter, Linda ; Grier, Holcombe E. ; Womer, Richard B. ; Randall, R ; Marcus, Karen J. ; McIlvaine, Elizabeth ; Krailo, Mark. / Age, Tumor Characteristics, and Treatment Regimen as Event Predictors in Ewing : A Children's Oncology Group Report. In: Sarcoma. 2015 ; Vol. 2015.
@article{400d81a1daab464aaa303908b669bdd4,
title = "Age, Tumor Characteristics, and Treatment Regimen as Event Predictors in Ewing: A Children's Oncology Group Report",
abstract = "Purpose. To associate baseline patient characteristics and relapse across consecutive COG studies. Methods. We analyzed risk factors for LESFT patients in three randomized COG trials. We evaluated age at enrollment, primary site, gender, tumor size, and treatment (as randomized). We estimated event-free survival (EFS, Kaplan-Meier) and compared risk across groups (log-rank test). Characteristics were assessed by proportional hazards regression with the characteristic of interest as the only component. Confidence intervals (CI) for RR were derived. Factors related to outcome at level 0.05 were included in a multivariate regression model. Results. Between 12/1988 and 8/2005, 1444 patients were enrolled and data current to 2001, 2004, or 2008 were used. Patients were with a median age of 12 years (0-45), 55{\%} male and 88{\%} Caucasian. The 5-year EFS was 68.3{\%} ± 1.3{\%}. In univariate analysis age, treatment, and tumor location were identified for inclusion in the multivariate model, and all remained significant (p < 0.01). Since tumor size was not collected in the last study, the other two were reanalyzed. This model identified age, treatment, tumor location, and tumor size as significant predictors. Conclusion. Age > 18 years, pelvic tumor, size > 8 cms, and chemotherapy without ifosfamide/etoposide significantly predict worse outcome. AEWS0031 is NCT00006734, INT0091 and INT0054 designed before 1993 (unregistered).",
author = "Neyssa Marina and Linda Granowetter and Grier, {Holcombe E.} and Womer, {Richard B.} and R Randall and Marcus, {Karen J.} and Elizabeth McIlvaine and Mark Krailo",
year = "2015",
month = "1",
day = "1",
doi = "10.1155/2015/927123",
language = "English (US)",
volume = "2015",
journal = "Sarcoma",
issn = "1357-714X",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Age, Tumor Characteristics, and Treatment Regimen as Event Predictors in Ewing

T2 - A Children's Oncology Group Report

AU - Marina, Neyssa

AU - Granowetter, Linda

AU - Grier, Holcombe E.

AU - Womer, Richard B.

AU - Randall, R

AU - Marcus, Karen J.

AU - McIlvaine, Elizabeth

AU - Krailo, Mark

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Purpose. To associate baseline patient characteristics and relapse across consecutive COG studies. Methods. We analyzed risk factors for LESFT patients in three randomized COG trials. We evaluated age at enrollment, primary site, gender, tumor size, and treatment (as randomized). We estimated event-free survival (EFS, Kaplan-Meier) and compared risk across groups (log-rank test). Characteristics were assessed by proportional hazards regression with the characteristic of interest as the only component. Confidence intervals (CI) for RR were derived. Factors related to outcome at level 0.05 were included in a multivariate regression model. Results. Between 12/1988 and 8/2005, 1444 patients were enrolled and data current to 2001, 2004, or 2008 were used. Patients were with a median age of 12 years (0-45), 55% male and 88% Caucasian. The 5-year EFS was 68.3% ± 1.3%. In univariate analysis age, treatment, and tumor location were identified for inclusion in the multivariate model, and all remained significant (p < 0.01). Since tumor size was not collected in the last study, the other two were reanalyzed. This model identified age, treatment, tumor location, and tumor size as significant predictors. Conclusion. Age > 18 years, pelvic tumor, size > 8 cms, and chemotherapy without ifosfamide/etoposide significantly predict worse outcome. AEWS0031 is NCT00006734, INT0091 and INT0054 designed before 1993 (unregistered).

AB - Purpose. To associate baseline patient characteristics and relapse across consecutive COG studies. Methods. We analyzed risk factors for LESFT patients in three randomized COG trials. We evaluated age at enrollment, primary site, gender, tumor size, and treatment (as randomized). We estimated event-free survival (EFS, Kaplan-Meier) and compared risk across groups (log-rank test). Characteristics were assessed by proportional hazards regression with the characteristic of interest as the only component. Confidence intervals (CI) for RR were derived. Factors related to outcome at level 0.05 were included in a multivariate regression model. Results. Between 12/1988 and 8/2005, 1444 patients were enrolled and data current to 2001, 2004, or 2008 were used. Patients were with a median age of 12 years (0-45), 55% male and 88% Caucasian. The 5-year EFS was 68.3% ± 1.3%. In univariate analysis age, treatment, and tumor location were identified for inclusion in the multivariate model, and all remained significant (p < 0.01). Since tumor size was not collected in the last study, the other two were reanalyzed. This model identified age, treatment, tumor location, and tumor size as significant predictors. Conclusion. Age > 18 years, pelvic tumor, size > 8 cms, and chemotherapy without ifosfamide/etoposide significantly predict worse outcome. AEWS0031 is NCT00006734, INT0091 and INT0054 designed before 1993 (unregistered).

UR - http://www.scopus.com/inward/record.url?scp=84945379250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945379250&partnerID=8YFLogxK

U2 - 10.1155/2015/927123

DO - 10.1155/2015/927123

M3 - Article

AN - SCOPUS:84945379250

VL - 2015

JO - Sarcoma

JF - Sarcoma

SN - 1357-714X

M1 - 927123

ER -